quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·22d
PRRelease
Axsome Therapeutics Inc. logo

Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions

AXSM· Axsome Therapeutics Inc.
Health Care
Original source

Companies

  • AXSM
    Axsome Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Feb 24UpdateWolfe Research$230.00
  • Jan 8UpdateMorgan Stanley$204.00
  • Oct 1UpdateB. Riley Securities$179.00
  • Sep 3UpdateWells Fargo$163.00
  • Jul 3UpdateMorgan Stanley$190.00
  • Jun 3UpdateOppenheimer$185.00

Related

  • INSIDER5h
    SEC Form 4 filed by Chief Operating Officer Jacobson Mark L.
  • INSIDER5h
    SEC Form 4 filed by Chief Executive Officer Tabuteau Herriot
  • INSIDER5h
    Chief Commercial Officer Maizel Ari exercised 7,500 shares at a strike of $70.73 and sold $1,368,150 worth of shares (7,500 units at $182.42) as part of a pre-agreed trading plan (SEC Form 4)
  • INSIDER5h
    SEC Form 4 filed by Chief Commercial Officer Maizel Ari
  • INSIDER5h
    SEC Form 4 filed by Chief Financial Officer Pizzie Nick
  • INSIDER5h
    SEC Form 4 filed by General Counsel Murdock Hunter R.
  • PR15d
    Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4
  • SEC22d
    Axsome Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022